文献速递心外重症与机械循环支持

糖尿病对左心室辅助装置植入患者结局的影响

Influence of Diabetes Mellitus on Outcomes in Patients After Left Ventricular Assist Device Implantation.
PubMed 文献 · Ann Thorac Surg · 2018-03-22

本研究纳入罗切斯特大学医学中心2008年5月至2014年6月接受HeartMate II连续流左心室辅助装置(LVAD)植入的95例非糖尿病患者和96例糖尿病患者,比较全因死亡率及感染、神经功能障碍、肾功能障碍和再住院率;糖尿病患者3年累积死亡概率高于非糖尿病患者(42% vs 21%,p=0.013),但两组不良事件率无显著差异,且LVAD前血糖控制程度(HbA1c <7.0% vs ≥7.0%)与死亡风险无统计学显著差异(HR 1.71,95%CI 0.72-4.08,p=0.223)。

要点

  • 糖尿病患者LVAD植入后3年累积死亡概率为42%,非糖尿病患者为21%(p=0.013)。
  • 两组感染、神经功能障碍和再住院总体发生率无显著差异。
  • LVAD前HbA1c <7.0%与≥7.0%的糖尿病患者死亡风险无统计学显著差异(HR 1.71,95%CI 0.72-4.08,p=0.223)。

核心结论

  • 接受LVAD植入的糖尿病患者较非糖尿病患者死亡风险更高。
  • 两组不良事件发生率无差异。
  • LVAD前糖尿病患者的血糖控制程度未发现影响死亡率。

研究设计与样本

  • 回顾性队列研究,纳入罗切斯特大学医学中心2008年5月至2014年6月接受HeartMate II连续流LVAD的95例非糖尿病患者和96例糖尿病患者。
  • 主要结局为全因死亡率,次要结局包括感染、神经功能障碍、肾功能障碍和再住院率。
  • 采用Kaplan-Meier生存分析和Cox模型。

主要发现

  • 随访期间,糖尿病患者32例(33%)和非糖尿病患者15例(16%)在LVAD植入后死亡。
  • 糖尿病患者3年累积死亡概率为42%,非糖尿病患者为21%(p=0.013)。
  • 两组感染、神经功能障碍和再住院总体发生率无显著差异。
  • 发生首次次要结局事件后,糖尿病患者死亡率仍高于非糖尿病患者。
  • LVAD前HbA1c <7.0%与HbA1c ≥7.0%的糖尿病患者死亡风险无统计学显著差异(HR 1.71,95%CI 0.72-4.08,p=0.223)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite previous studies, the mortality risk of patients with diabetes mellitus after left ventricular assist device (LVAD) implant remains unclear. In addition, the relationship between the degree of glycemic control and long-term mortality risk in LVAD patients with diabetes has not been established. METHODS: Ninety-five nondiabetic patients and 96 diabetic patients from the University of Rochester Medical Center who received a HeartMate II (Thoratec, Pleasanton, CA) continuous-flow LVAD between May 2008 and June 2014 were included in this study. The primary outcome was all-cause mortality. Secondary outcomes included rates of infection, neurologic dysfunction, renal dysfunction, and rehospitalization. Kaplan-Meier survival analyses and Cox models were utilized. RESULTS: During follow-up, 32 diabetic patients (33%) and 15 nondiabetic patients (16%) died after LVAD implantation. Cumulative probability of death was higher for diabetic patients when compared with nondiabetic patients (42% versus 21% at 3 years, p = 0.013). There were no significant differences in overall rates of infection, neurologic dysfunction, and rehospitalization between the two groups. However, after an initial secondary outcome event, diabetic patients continued to have a higher mortality rate when compared with nondiabetic patients. There was no statistically significant difference in the risk of death between diabetic patients with pre-LVAD hemoglobin A1c less than 7.0% and diabetic patients with pre-LVAD hemoglobin A1c 7.0% or greater (hazard ratio 1.71, 95% confidence interval: 0.72 to 4.08, p = 0.223). CONCLUSIONS: Diabetic patients who underwent LVAD implantation had a higher risk of death compared with nondiabetic patients. Adverse event rates did not differ between the two groups. Finally, the degree of glycemic control in diabetic patients before LVAD was not found to influence mortality.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Usoh CO, Sherazi S, Szepietowska B, et al. Influence of Diabetes Mellitus on Outcomes in Patients After Left Ventricular Assist Device Implantation. Ann Thorac Surg. 2018. PMID: 29577927. doi:10.1016/j.athoracsur.2018.02.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。